Patent EP0227619A2 successfully refreshed from Google Patents.
EP0227619A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
New protein and its use
Assignee: Kabigen AB
•
Filing: 1986-12-02
•
Granted: —
•
Expires: 2006-12-02
Abstract
Abstract Protein comprising at the N-terminal thereof the amino acid sequence: NH₂-Thr¹-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala¹⁰-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe²⁰-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-R wherein R is an amino acid sequence such that the overall apparent molecular weight of the protein is about 7000; method of stimulating brain cell growth; composition for therapeutic or diagnostic use; and a method for diagnosing the presence of brain cell growth factor.
Inventors
- 👤 Vicki Rubian Sara
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 13:57
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/65; A; A61; A61P; A61P25/00; A61K; A61K38/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
31 words
Protein comprising at the N-terminal thereof the amino acid sequence: NH₂-Thr¹-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala¹⁰-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe²⁰-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-R wherein R is an amino acid sequence such that the overall apparent molecular weight of the protein is about 7000.
Claim 2
Dependent Claim
31 words
Protein comprising at the N-terminal thereof the amino acid sequence: NH₂-Thr¹-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala¹⁰-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe²⁰-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-R wherein R is an amino acid sequence such that the overall apparent molecular weight of the protein is about 7000.
Claim 3
Dependent Claim
29 words
Protein according to claim 1, wherein R is such that the overall composition of the protein corresponds to that of IGF-1 excluding the three N-terminal amino acid residues thereof.
Claim 4
Dependent Claim
29 words
Protein according to claim 2, wherein R is such that the overall structure of the protein corresponds to that of IGF-1 excluding the three N-terminal amino acid residues thereof.
Claim 5
Dependent Claim
31 words
A method of stimulating neural tissue growth in mammals including man, comprising administering an effective amount of the protein of claim 1, 2 or 3 to a mammal subject to treatment.
Claim 6
Dependent Claim
32 words
A composition for therapeutic or diagnostic use comprising in combination an active amount of the protein of any of claims 1 to 3 in combination with a nontoxic and noninterfering carrier therefor.
Claim 7
Dependent Claim
41 words
A method for diagnosing the presence of neural tissue growth factor in physiological fluids and tissues using the immunological interaction between antibodies generated by the protein of claim 1 and antigen comprised in a fluid or tissue sample subject to diagnosis.
Claim 8
Dependent Claim
50 words
A method according to claim 6 comprising the steps: a) generating antibodies to the protein of claim 1; b) recording inhibition of interaction between antibodies obtained under step a) and a labelled protein according to claim 1 by adding varying amounts of a fluid or tissue sample subject to test.
Claim 9
Dependent Claim
11 words
A method according to claim 4 applied to brain cell growth.
Claim 10
Dependent Claim
11 words
A method according to claim 6 applied to brain cell growth.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.